|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
IMMUNOBIOLOGY
From the Myeloma and Transplantation Research Center,
University of Arkansas for Medical Science, Little Rock.
The idiotype protein, secreted by myeloma plasma cells, is a
tumor-specific but weak antigen. Idiotype-based immunotherapy has been
explored in myeloma patients with disappointing results. It is
conceivable that myeloma cells contain a multitude of tumor antigens
that can more effectively stimulate antitumor T cells. To explore the
possibility of using whole myeloma cells as a source of tumor antigens
for immunotherapy, the current study was undertaken to generate and
examine the function of myeloma-specific cytotoxic T lymphocytes
(CTLs) by using dendritic cells (DCs) pulsed with myeloma cell lysates
as stimulating cells. After repeated stimulation, specific CTL lines,
containing CD4+ and CD8+ T cells, were
generated from myeloma patients. Our results show that these T cells
not only recognized and lysed autologous myeloma protein-pulsed DCs,
they also killed autologous primary myeloma cells. Occasionally, CTLs
responded to autologous idiotype-pulsed DCs and to allogeneic primary
myeloma cells. No cytolytic activity, however, was detected against
autologous lymphocytes including B cells, suggesting that the T cells
acted specifically against myeloma cells. Cytotoxicity against target
cells was major histocompatibility complex class 1 and, to a lesser
extent, class 2 restricted and was dependent mainly on the
perforin-mediated pathway. CTLs secreted predominantly interferon- Multiple myeloma (MM) is a B-cell malignancy
accounting for 1% of all cancers and 10% of all hematologic
malignancies. With conventional chemotherapy, complete remission rates
have not exceeded 5%, and median survival time has not been extended
beyond 3 years.1,2 High-dose chemotherapy followed by stem
cell support results in long-term disease-free survival in one third of
myeloma patients.3 However, relapse of the underlying
disease remains the primary cause of treatment failure.4
Therefore, novel alternative therapeutic strategies aiming at improving
the outcome in these patients are necessary.
Vaccines based on immunization against one or more specific tumor
antigens or on adoptive transfer of ex vivo-generated lymphocytes with
high levels of specific reactivity against tumor antigens represent an
attractive approach.5-8 In MM, the idiotype (Id) determinant of the paraprotein can be regarded as a tumor-specific marker, and it has been used for immunotherapy.9-14
Although modest and transient, Id-specific immune responses can be
induced in 25% to 100% of myeloma patients. However, clinical
responses, defined by significant reductions in M components,
have been observed in few patients.11,13 This may be
attributed to the fact that Id is a weak antigen15 and that
high concentrations of circulating Id protein in myeloma patients might
suppress or even deplete Id-specific T cells.16 Thus, a
search for other myeloma antigens is warranted for the development of
more efficient immunotherapy strategies in this disease.
Myeloma cells contain a multitude of tumor antigens that can stimulate
an increased repertoire of antitumor T cells. The objectives of this
study were to generate myeloma cell-specific cytotoxic T lymphocytes
(CTLs) from myeloma patients and to examine the efficacy of these T
cells in the lysis of their target cells, among them tumor
lysate-pulsed dendritic cells (DCs), autologous primary myeloma cells,
and normal blood lymphocytes including B cells. Specific CTLs were
generated using autologous adherent peripheral blood mononuclear
cell-derived DCs pulsed with myeloma lysates as antigen-presenting
cells (APCs). We show for the first time that myeloma lysate-pulsed
DCs reproducibly generate myeloma cell-specific CTLs capable of
killing autologous primary myeloma cells but not autologous lymphocytes.
Isolation of primary myeloma plasma cells and preparation of
tumor lysate
Fresh bone marrow aspirates from the patients were collected, and bone
marrow mononuclear cells were separated using Ficoll-Hypaque (Amersham
Pharmacia Biotech AB, Uppsala, Sweden) density centrifugation. Bone
marrow mononuclear cells from the patients contained more than 90%
CD138+CD38++ myeloma plasma cells, determined
by flow cytometry analysis. Aliquots of the myeloma plasma cells were
cryopreserved in Myeloma cell lysate was prepared by 5 rounds of freezing and thawing to
lyse the myeloma cells. Nuclear debris was removed by centrifugation
(600 rpm, 10 minutes). Cell lysate was filtered, and the protein was
quantified before use.
Isolation of idiotype protein
Immunophenotyping Immunophenotyping was carried out on all the cultured cells using a fluorescence-activated cell sorter scan (FACScan; Becton Dickinson, San Jose, CA) and was analyzed using the Lysis II program. Briefly, cells were first washed twice in washing buffer (phosphate-buffered saline + 2% bovine serum albumin and 0.5% sodium azide). Phycoerythrin- or fluorescein isothiocyanate-conjugated monoclonal antibodies (Immunotech, Marseilles, France), at the manufacturer's recommended concentrations, were added to each cell pellet, and the cells were incubated on ice for 30 minutes before they were washed 3 times and were resuspended in phosphate-buffered saline ready for analysis. Controls consisted of cells stained with irrelevant mouse IgG antibodies.Generation of dendritic cells Peripheral blood mononuclear cells (PBMCs) from the same 4 patients were isolated from leukapheresis-collected blood cells using Ficoll-Hypaque (Amersham Pharmacia Biotech AB) gradient centrifugation. Aliquots of PBMCs were cryopreserved in 80°C until use.
Cryopreserved PBMCs were recovered and resuspended at
5 × 106 cells/mL in RPMI 1640 supplemented with 10%
fetal calf serum, 1 mM glutamine, 100 U/mL penicillin, and 100 µg/mL
streptomycin (referred to as complete medium) (Gibco, Grand Island,
NY). PBMCs were incubated in a humidified incubator at 37°C in 5%
CO2 for 2 hours to allow cell adhesion. Nonadherent cells
were removed by gentle washes. Adherent cells were then cultured in
complete medium supplemented with granulocyte
macrophage-colony-stimulating factor (100 ng/mL) and interleukin
(IL)-4 (100 ng/mL; both from Schering-Plough Research Institute,
Kenilworth, NJ) for 7 days, with the further addition of cytokines on
days 3 and 5. During culture, tumor lysates of autologous or allogeneic
myeloma cells (both at 100 µg/mL) were added on days 1 and 5 to pulse
the cells. After 7 days of culture, cells were harvested and
phenotypically characterized to assure they met the typical phenotype
of immature DCs that is, CD3 , CD4,
CD14, CD19, CD83,
CD1a+, CD40+, CD80+,
CD86+, HLA-DR+, and
HLA-ABC+.17,18
Generation of tumor lysate-specific cytotoxic T lymphocytes CTLs were elicited from autologous PBMCs using repeated stimulation by DCs pulsed with myeloma cell lysates. Washed PBMCs (2 × 106/mL) were resuspended in complete medium containing recombinant IL-2 (30 IU/mL; Chiron, Emeryville, CA) and IL-7 (5 ng/mL; R&D Systems, Minneapolis, MN), and lysate-pulsed autologous DCs (2 × 105/mL) were added to primary cultures. Cells were incubated in 50-mL tissue culture flasks at 37°C in 5% CO2-95% air. Responder cells were restimulated with lysate-pulsed autologous DCs every 2 weeks, and the cultures were fed every 5 days with fresh medium containing recombinant IL-2 and IL-7. After 3 to 4 cycles of antigen stimulation and selection, T-cell lines were established, and cells were expanded in complete medium containing recombinant IL-2 (30 IU/mL) and IL-7 (5 ng/mL) for 2 weeks and were subjected to functional tests.Proliferation assays T cells (5 × 104/100 µL/well) were seeded into 96-well flat-bottomed tissue culture plates. DCs pulsed with Id protein or lysates of the autologous tumor and an allogeneic tumor from another patient or primary myeloma cells were added to cultures in different concentrations, and cultures were incubated at 37°C in 5% CO2-95% air for 4 days. T-cell proliferation was measured using overnight incubation with [3H]-thymidine (0.0185 MBq/well; Amersham Pharmacia Biotech, Piscataway, NJ). Results from triplicate cultures are given as the arithmetic means.Enzyme-linked immunospot assay Detailed methods of the enzyme-linked immunospot (ELISPOT) assay for the enumeration of antigen-specific cytokine-secreting cells have been described.19,20 Briefly, plates (Millititer-HAM; Millipore, Bedford, MA) were coated with mouse monoclonal antihuman IFN- (1 µg/mL), IL-4 (2.5 µg/mL), or TNF- (2.5 µg/mL) (R&D
Systems). Cultured T cells (104 cells/well) were added and
incubated with Id- or lysate-pulsed DCs or with primary myeloma cells
for 36 hours at 37°C. Cells incubated without target cells or with
phytohemagglutinin (10 µg/mL; Sigma) were used as controls. After
incubation, cells were detached from the plates by washing, and
polyclonal antihuman IFN- (250 ng/mL), IL-4 (1 µg/mL) (R&D
Systems), or TNF- (4 µg/mL; Serotec, Oxford, United Kingdom) was
added and incubated for 2 hours. Spots were developed by sequential
incubation with biotinylated antigoat (1/500; IFN- and IL-4) or
antirabbit (1/100; TNF-) antibodies (Vector Laboratories;
Burlingame, CA), followed by peroxidase staining, using the substrate
3-amino-9-ethyl-carbazol (Sigma). Spots corresponding to the
cytokine-secreting cells were enumerated under a dissection microscope
(Stemi SV6; Zeiss, Jena, Germany). All samples were run in duplicate.
Data are expressed as the mean number of cytokine-secreting cells per
104 T cells.
Cytotoxicity assays Target cells included autologous DCs pulsed with autologous or allogeneic tumor lysates or Id proteins, thawed autologous or allogeneic primary myeloma cells from another patient, and Ficoll-Hypaque centrifuged to get rid of dead cells, autologous PBMCs, purified peripheral blood B cells, or Epstein-Barr virus (EBV)-transformed B cells from the patients. Cells were labeled with chromium Cr 51 for 1 hour and with 1 × 104 target cells/well mixed with various numbers of effector cells in a standard 4-hour cytotoxicity assay using 96-well round-bottomed plates. All assays were performed at least in triplicate. Results are shown as mean percentage 51Cr release calculated as follows: [(sample counts spontaneous counts)/(maximum
counts spontaneous counts)] × 100. Spontaneous release was
less than 25% of the maximum 51Cr uptake.
To determine whether cytolytic activity was restricted by major histocompatibility complex (MHC) class 1 or 2 molecules, antibodies against HLA-ABC (W6/32; Serotec) or HLA-DR (B8.12.2; Immunotech) and an isotopic control mouse IgG (Immunotech) at 10 µg/mL were added to the cultures at the initiation of the assay. Inhibition of perforin- and Fas-mediated pathways of cytolysis Concanamycin A (CMA; Sigma), an inhibitor of vacuolar type H+-adenosine triphosphate (ATPase), and Brefeldin A (Sigma) were used as selective inhibitors of perforin-mediated and Fas-mediated cytotoxicity,21 respectively. Effector cells were pretreated with 100 nM CMA or 10 µM Brefeldin A for 2 hours and were assayed for cytotoxicity in the presence of the drugs.
Specific proliferative T-cell response against tumor lysate-pulsed dendritic cells DCs were successfully generated from peripheral blood adherent cells of myeloma patients after 7 days of culture. Immunophenotyping showed that the cells were CD3, CD4,
CD14, CD19, CD83 and
CD1a+, CD40+, CD80+,
CD86+, HLA-DR+, HLA-ABC+ (data
not shown).
We initially examined the immune response of unstimulated autologous T
cells to myeloma proteins in primary cultures. No significant proliferative response was observed in any of the repeated experiments using either freshly recovered PBMCs or IL-2 (50 IU/mL) pretreated PBMCs (data not shown). However, after repeated rounds of T-cell stimulation with myeloma lysate-pulsed DCs, specific T-cell lines were
generated and propagated from PBMCs of the myeloma patients. Specific
proliferative responses were observed when T cells were rechallenged
with the autologous tumor lysate-pulsed DCs and, to a lesser extent,
autologous primary myeloma cells (Figure
1A-D). Interestingly, a weak but positive
proliferative response to autologous Id-pulsed DCs was also observed in
the T cells from patients 1 and 4, suggesting that the CTLs contained
Id-specific T cells. No proliferative response was noted when T cells
were restimulated with autologous DCs or DCs pulsed with the allogeneic
tumor lysates. These results, therefore, suggested that the autologous
T cells recognized patient-specific immune epitope(s) of myeloma
antigens, presented by either primed DCs or primary myeloma cells.
The T-cell proliferative responses observed in the patients were partially blocked by monomorphic monoclonal antibody to MHC class 1 and 2 molecules. T-cell responses induced by DCs pulsed with tumor lysates were inhibited by MHC class 1 (HLA-ABC) and class 2 (HLA-DR) antibodies (50%-70% inhibition), whereas the response induced by primary myeloma cells was inhibited predominantly by the MHC class 1 antibody (60%-80% inhibition). A combination of MHC class 1 and 2 antibodies produced a synergistic (greater than 90%) inhibition of the proliferative response against pulsed DCs. These results indicate that the recognition of T-cell epitopes in tumor lysates presented by DCs was mediated through MHC class 1 and 2 molecules, whereas those presented by primary myeloma cells were mainly on the class 1 molecules. Consistent with these findings, flow cytometry analysis showed that the tumor lysate-primed T-cell lines consisted of approximately 45% CD8+ and 55% CD4+ T cells. No CD16+ or CD56+ NK cells were present in these cell lines. Cytokine production of the T cells To characterize the cytokine-secretion profile and its corresponding subsets of T cells, an ELISPOT assay was used to detect cytokine secretion. As exemplified by the experiments depicted in Figure 2A,B using T cells from patients 1 and 2, small numbers of IFN-- and TNF--secreting cells were
detected in the unstimulated T cells. After rechallenge with tumor
lysate-pulsed autologous DCs or primary myeloma cells, elevated
numbers of IFN-- and TNF--secreting cells were demonstrated.
IL-4-secreting cells were rare or undetectable. T cells stimulated
with autologous Id-pulsed DCs had slight increases in the numbers of
IFN-- and TNF--secreting cells. Incubation with nonpulsed DCs
or with DCs pulsed with the allogeneic myeloma protein did not
significantly alter the number of cytokine-secreting cells. These
results were reproduced in repeated experiments and with cells from the
other 2 patients (data not shown), and they indicate that the effector
cells were type-1 T cells.22,23
Cytolytic activity of the T cells against tumor lysate-pulsed dendritic cells and primary myeloma cells in vitro To test whether a specific CTL response could be effectively induced with tumor lysate-pulsed DCs, we assessed the cytotoxic activity of the T cells in vitro. Autologous DCs and DCs pulsed with autologous or allogeneic myeloma protein were used as target cells. As shown in Figure 3A, the CTL lines lysed the autologous DCs pulsed with myeloma lysate. No significant killing of autologous unpulsed DCs or DCs pulsed with the allogeneic myeloma cell lysates was observed (Figure 3B). Results indicate that the T cells were able to mediate tumor- and patient-specific cytotoxicity. As expected, when we used autologous Id-pulsed DCs as target cells, we noted that the CTLs from patients 1 and 4, but not patients 2 and 3, lysed this target (Figure 3B), suggesting that Id protein was part of the immune epitopes that had been presented to T cells.
To determine MHC restriction of these CTL lines, we studied the inhibitory effect of anti-MHC antibodies on their cytolysis activity. Blocking of MHC class 1 (HLA-ABC) or class 2 (HLA-DR) molecules on the target cells resulted in an inhibition of the cytotoxicity of the CTL against autologous lysate-pulsed DCs (Figure 3C; data from patients 1 and 2). The result further confirmed that the immune epitopes within myeloma proteins were presented in association with MHC class 1 and class 2 molecules. To evaluate whether the tumor lysate-specific immune response is relevant to the clinical antimyeloma effect, we examined whether CTLs could lyse autologous primary myeloma cells. Using the CTL lines generated from the patients as effector cells, significant killing of the autologous myeloma cells was observed (Figure 3B). CTLs from patient 2 also killed allogeneic primary myeloma cells (from patient 1), though to a lesser extent, suggesting that there were shared myeloma antigens and MHC molecules between these 2 patients. Blocking of MHC class 1 but not of MHC class 2 molecules of the target cells inhibited significantly (more than 80%) the cytotoxicity of the CTLs. Thus, the results demonstrate that tumor lysate-primed CTLs are capable of mediating strong, MHC class 1-restricted cytotoxicity against autologous primary myeloma cells in vitro. Cytolytic activity of the T cells against autologous lymphocytes To evaluate whether tumor lysate-primed CTLs might be killing normal blood cells, especially B cells, we performed experiments to examine the cytotoxicity of CTLs against autologous PBMCs, purified B cells, and EBV-transformed B cells, and we compared the results with cytotoxicity against primary myeloma cells. As shown in Figure 4, CTLs killed only the primary myeloma cells. No cytolytic activity was observed against autologous PBMCs, B cells, or NK-sensitive target cells K562. Thus, these results suggest that the CTLs specifically targeted myeloma cells.
Myeloma-specific cytotoxic T-cell response is mediated by the perforin exocytosis pathway To investigate whether the cytotoxic function of tumor lysate-primed CTLs was mediated by the FasL/Fas or perforin systems, we examined the effect of CMA and Brefeldin A, selected inhibitors of perforin-mediated and Fas-mediated cytotoxicity,21 respectively. Treatment of the CTL lines with Brefeldin A induced less than 20% inhibition in the lytic activity of myeloma-specific CTLs (Figure 5; data from patients 1 and 2), indicating that the Fas/FasL system was not the main pathway of cytotoxicity mediated by these CTLs. This result was supported by flow cytometry analysis showing low or absent FasL expression by the T cells (data not shown). In contrast, when we studied the inhibition of cytotoxicity by pretreatment with CMA, cytolytic activity was almost completely abrogated (Figure 5). Treatment of the CTLs with Brefeldin A or CMA did not induce apoptosis of these CTLs (data not shown). Taken together, these results indicate that the cytotoxic function of myeloma-specific CTLs was mediated mainly by the perforin-dependent pathway.
Myeloma cells can be a source of tumor antigens for immunotherapy in MM. With the exception of Id protein, no other antigens have been identified yet that can be used for this purpose. In the current study, by using tumor lysate-pulsed DCs as APCs, we generated autologous tumor lysate-primed CTL lines from 4 patients with MM. These CTLs were able to recognize and lyse autologous tumor lysate-pulsed DCs and autologous primary myeloma plasma cells, justifying the exploration of myeloma cell-based immunotherapy in MM. Interestingly, in some patients the CTLs killed Id-pulsed DCs and, to a lesser extent, allogeneic myeloma cells, suggesting that Id protein might be part of the tumor antigen presented to T cells and that myeloma patients have identical antigens presented by common MHC molecules. Indeed, patients 1 and 2 did have identical MHC class 1 alleles (data not shown). Results observed in this study indicate that myeloma cell lysates
contain epitopes recognized by T cells mediating proliferative and
cytotoxic responses in an MHC-restricted manner. Proliferative and
cytotoxic responses of the CTLs generated from the patients were
restricted by MHC class 1 and class 2 molecules, and the CTLs contained
CD4+ and CD8+ T cells. Furthermore, the
cytokine release by the CTLs was analyzed by the ELISPOT assay.
Production of a significant amount of IFN- It is generally accepted that tumors growing in vivo naturally provide antigens to APCs either by shedding from the surfaces of viable cells or by fragmentation of dead tumor cells. Such processes elicit the induction of cellular immune responses by mechanisms that include cross-priming.26 The use of tumor cells, either as lysate or apoptotic cells,27-29 as a possible source of tumor antigens for DC pulsing has several potential advantages, among them mimicking the physiological processes by which a growing tumor induces an immune response in vivo and augmenting a broader T-cell immune response to tumor-associated antigens that would not be obtained by pulsing DCs with a single defined tumor antigen (peptides or protein). However, because tumor antigens may be shared with normal host cells, immunotherapy with tumor cell-pulsed DCs may potentially induce autoimmunity or autoimmune diseases.30 Therefore, we have examined whether myeloma cell lysate-primed CTLs lysed normal lymphocytes, especially B cells. Our results show clearly that the CTLs did not kill autologous PBMCs, purified B cells, or EBV-transformed B cells, suggesting that the CTLs primed by lysate-pulsed DCs are myeloma specific. These CTLs may be promising effector cells for immunotherapy in this disease. Plasma cells represent the terminal differentiation stage of B-cell development. In MM, plasma cells usually constitute at least 10% and can even reach more than 90% of the total bone marrow cell count.31 One important aspect is whether the myeloma cells can be recognized and regulated by tumor-specific T cells. Our previous study has shown that freshly isolated primary myeloma cells can activate T cells; they stimulate alloreactive T cells and present recall antigens to autologous T cells,25 suggesting that myeloma cells can act as APCs. The current study demonstrates that tumor lysate-primed CTLs lyse autologous plasma cells in an MHC class 1-restricted manner, indicating that the tumor cells process tumor antigens and present the antigenic peptides in the context of MHC class 1 molecules on the cell surface. Taken together, these findings indicate that myeloma plasma cells express tumor antigens and are susceptible to tumor-specific T cell-mediated lysis. CTL recognition of target cells through their T-cell receptor can activate 2 distinct mechanisms of cell lysis.32,33 The first is granule exocytosis, mediated by pore-forming perforin and granzymes A and B. The second involves interaction between the Fas ligand on effector cells and Fas molecules expressed on the target cells. In the current study, CTLs appeared to lyse the target cells mainly through the perforin-mediated pathway because CMA, the selective blocking agent, induced 90% of inhibition of cytotoxicity. Brefeldin A, a selective inhibitor of the Fas-mediated pathway, resulted in less than 20% inhibition. Hence, these findings are in agreement with our previous studies.34,35 This is important in view of published results on Fas expression on myeloma cells. Dalton et al36 have shown that Fas antigen point mutations were detected in 10% of patient bone marrow samples. Mutations were located in the cytoplasmic region, which is involved in the transduction of an apoptotic signal and thus renders the cells resistant to Fas-induced apoptosis. Furthermore, they found that drug-resistant myeloma cells also became resistant to Fas-mediated apoptosis.37 Thus, the use of cytotoxic CTLs through the Fas-mediated pathway may have limited benefit, but pore-forming CTLs can be used for the treatment of drug-resistant myeloma. In conclusion, our results demonstrate that by using DCs as APCs, autologous myeloma-specific CTLs can be generated from myeloma patients. These T cells are efficient in killing lysate-pulsed autologous DCs and primary myeloma cells, but not blood lymphocytes, including B cells from patients. Thus, our study provides strong and direct evidence to support the application of tumor cell-based immunotherapies in MM.
Submitted June 26, 2001; accepted December 18, 2001.
Supported in part by grants from the Leukemia and Lymphoma Society (6548-00), the Multiple Myeloma Research Foundation and McCarty Cancer Foundation, and the National Cancer Institute (PO1-CA55819).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Qing Yi, Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Slot 776, 4301 West Markham St, Little Rock, AR 72205; e-mail: yiqing{at}uams.edu.
1. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med. 1994;7:484-489. 2. Barlogie B. Plasma cell myeloma. In: Beutler E,Lichtman M,Coller B,Kipps T, eds. William's Hematology. 5th ed. New York, NY: McGraw-Hill; 1995:1109-1126.
3.
Attal M, Harousseau JC, Stoppa AM, et al.
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma.
N Engl J Med.
1996;335:91-97 4. Tricot G, Jagannath S, Vesole DH, Crowley J, Barlogie B. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant. 1995;16:7-11[Medline] [Order article via Infotrieve]. 5. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol. 1995;154:3961-3968[Abstract].
6.
Jager E, Chen YT, Drijfhout JW, et al.
Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.
J Exp Med.
1998;187:265-270
7.
Hsu FJ, Caspar CB, Czerwinski D, et al.
Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: long-term results of a clinical trial.
Blood.
1997;89:3129-3135 8. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today. 1997;18:175-182[CrossRef][Medline] [Order article via Infotrieve]. 9. Kwak LW, Taub DD, Duffey PL, et al. Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. Lancet. 1995;345:1016-1020[CrossRef][Medline] [Order article via Infotrieve]. 10. Bergenbrant S, Yi Q, Österborg A, et al. Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br J Haematol. 1996;92:840-846[CrossRef][Medline] [Order article via Infotrieve].
11.
Österborg A, Yi Q, Henriksson L, et al.
Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses.
Blood.
1998;91:2459-2466 12. Wen YJ, Ling M, Bailey-Wood R, Lim SH. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res. 1998;4:957-962[Abstract]. 13. Lim SH, Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer. 1999;83:215-222[CrossRef][Medline] [Order article via Infotrieve].
14.
Reichardt VL, Okada CY, Liso A, et al.
Idiotypic vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasibility study.
Blood.
1999;93:2411-2419 15. Bogen B, Malissen B, Haas W. Idiotype-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur J Immunol. 1986;16:1373-1378[Medline] [Order article via Infotrieve]. 16. Bogen B, Schenck K, Munthe LA, Dembic Z. Deletion of idiotype-specific T cells in multiple myeloma. Acta Oncol. 2000;39:783-788[CrossRef][Medline] [Order article via Infotrieve]. 17. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9:271-296[CrossRef][Medline] [Order article via Infotrieve].
18.
Sallusto F, Lanzavecchia A.
Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor 19. Yi Q, Bergenbrant S, Österborg A, et al. T-cell stimulation induced by idiotypes on monoclonal immunoglobulins in patients with monoclonal gammopathies. Scand J Immunol. 1993;38:529-534[CrossRef][Medline] [Order article via Infotrieve].
20.
Yi Q, Österborg A, Bergenbrant S, Mellstedt H, Holm G, Lefvert AK.
Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies.
Blood.
1995;86:3043-3049 21. Kataoka T, Shinohara N, Takayama H, et al. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol. 1996;156:3678-3686[Abstract]. 22. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996;17:138-146[CrossRef][Medline] [Order article via Infotrieve]. 23. Cox FEG, Liew FY. T-cell subsets and cytokines in parasitic infections. Immunol Today. 1992;13:445-448[CrossRef][Medline] [Order article via Infotrieve].
24.
Duperray C, Klein B, Durie BGM, et al.
Phenotypic analysis of human myeloma cell lines.
Blood.
1989;73:566-572
25.
Yi Q, Dabadghao S, Österborg A, Bergenbrant S, Holm G.
Myeloma bone marrow plasma cells: evidence for their capacity as antigen-presenting cells.
Blood.
1997;90:1960-1967
26.
Bevan MJ.
Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay.
J Exp Med.
1976;143:1283-1288
27.
Fields RC, Shimizu K, Mule JJ.
Murine dendritic cells pulsed with whole tumor lysates mediates potent antitumor immune responses in vitro and in vivo.
Proc Natl Acad Sci U S A.
1998;95:9482-9487 28. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332[CrossRef][Medline] [Order article via Infotrieve].
29.
Russo V, Tanzarella S, Dalerba P, et al.
Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class Irestricted T cell response.
Proc Natl Acad Sci U S A.
2000;97:2185-2190
30.
Ludewig B, Ochsenbein AF, Odermatt B, et al.
Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease.
J Exp Med.
2000;191:795-804 31. Kyle R. Diagnostic criteria of multiple myeloma. Hematol Oncol Clin North Am. 1992;6:347-358[Medline] [Order article via Infotrieve].
32.
Kagi D, Vignaux F, Ledermann B, et al.
Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity.
Science.
1994;265:528-530 33. Kojima H, Shinohara N, Hanaoka S, et al. Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes. Immunity. 1994;1:357-364[CrossRef][Medline] [Order article via Infotrieve]. 34. Chiriva-Internati M, Du J, Cannon M, Barlogie B, Yi Q. Myeloma-reactive allospecific cytotoxic T lymphocytes lyse target cells by the granule exocytosis pathway. Br J Haematol. 2001;112:410-420[CrossRef][Medline] [Order article via Infotrieve].
35.
Wen YJ, Barlogie B, Yi Q.
Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells.
Blood.
2001;97:1750-1755
36.
Landowski TH, Qu N, Buyuksal I, Painter JS, Dalton WS.
Mutation in the Fas antigen in patients with multiple myeloma.
Blood.
1997;90:4266-4270
37.
Landowski TH, Gleason-Guzman MC, Dalton WS.
Selection for drug resistance results in resistance to Fas-mediated apoptosis.
Blood.
1997;89:1854-1861
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  S. Hong, J. Qian, J. Yang, H. Li, L. W. Kwak, and Q. Yi Roles of Idiotype-Specific T Cells in Myeloma Cell Growth and Survival: Th1 and CTL Cells Are Tumoricidal while Th2 Cells Promote Tumor Growth Cancer Res., October 15, 2008; 68(20): 8456 - 8464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Grube, S. Moritz, E. C. Obermann, K. Rezvani, A. Mackensen, R. Andreesen, and E. Holler CD8+ T cells Reactive to Survivin Antigen in Patients with Multiple Myeloma Clin. Cancer Res., February 1, 2007; 13(3): 1053 - 1060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wang, S. Hong, J. Yang, J. Qian, X. Zhang, E. Shpall, L. W. Kwak, and Q. Yi Optimizing immunotherapy in multiple myeloma: restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells Blood, December 15, 2006; 108(13): 4071 - 4077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wang, J. Yang, J. Qian, M. Wezeman, L. W. Kwak, and Q. Yi Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma Blood, March 15, 2006; 107(6): 2432 - 2439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Motomura, S. Senju, T. Nakatsura, H. Matsuyoshi, S. Hirata, M. Monji, H. Komori, D. Fukuma, H. Baba, and Y. Nishimura Embryonic Stem Cell-Derived Dendritic Cells Expressing Glypican-3, a Recently Identified Oncofetal Antigen, Induce Protective Immunity against Highly Metastatic Mouse Melanoma, B16-F10 Cancer Res., February 15, 2006; 66(4): 2414 - 2422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jalili, S. Ozaki, T. Hara, H. Shibata, T. Hashimoto, M. Abe, Y. Nishioka, and T. Matsumoto Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma Blood, November 15, 2005; 106(10): 3538 - 3545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Geffroy-Luseau, A. Moreau-Aubry, R. Bataille, and C. Pellat-Deceunynck Allogeneic T lymphocytes as a source of peptide-dependent T cells specific for myeloma cells Int. Immunol., September 1, 2005; 17(9): 1193 - 1200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. Rew, K. Peggs, I. Sanjuan, A. R. Pizzey, Y. Koishihara, S. Kawai, M. Kosaka, S. Ozaki, B. Chain, and K. L. Yong Generation of Potent Antitumor CTL from Patients with Multiple Myeloma Directed against HM1.24 Clin. Cancer Res., May 1, 2005; 11(9): 3377 - 3384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bae, J. A. Martinson, and H. G. Klingemann Identification of CD19 and CD20 Peptides for Induction of Antigen-Specific CTLs against B-Cell Malignancies Clin. Cancer Res., February 15, 2005; 11(4): 1629 - 1638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Barlogie, J. Shaughnessy, G. Tricot, J. Jacobson, M. Zangari, E. Anaissie, R. Walker, and J. Crowley Treatment of multiple myeloma Blood, January 1, 2004; 103(1): 20 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Dhodapkar, J. Krasovsky, K. Osman, and M. D. Geller Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal Gammopathy J. Exp. Med., December 1, 2003; 198(11): 1753 - 1757. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Kircher, J. R. Allport, E. E. Graves, V. Love, L. Josephson, A. H. Lichtman, and R. Weissleder In Vivo High Resolution Three-Dimensional Imaging of Antigen-Specific Cytotoxic T-Lymphocyte Trafficking to Tumors Cancer Res., October 15, 2003; 63(20): 6838 - 6846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. M. Mackus, F. N. J. Frakking, A. Grummels, L. E. Gamadia, G. J. de Bree, D. Hamann, R. A. W. van Lier, and M. H. J. van Oers Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia Blood, August 1, 2003; 102(3): 1057 - 1063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Hansson, H. Rabbani, J. Fagerberg, A. Osterborg, and H. Mellstedt T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma Blood, June 15, 2003; 101(12): 4930 - 4936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Parkhurst, C. DePan, J. P. Riley, S. A. Rosenberg, and S. Shu Hybrids of Dendritic Cells and Tumor Cells Generated by Electrofusion Simultaneously Present Immunodominant Epitopes from Multiple Human Tumor-Associated Antigens in the Context of MHC Class I and Class II Molecules J. Immunol., May 15, 2003; 170(10): 5317 - 5325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Chun, J. Lee, H. S. Cheong, and K.-Y. Lee Tumor Eradication by Hepatitis B Virus X Antigen-Specific CD8+ T Cells in Xenografted Nude Mice J. Immunol., February 1, 2003; 170(3): 1183 - 1190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Gatza and C. Y. Okada Tumor Cell Lysate-Pulsed Dendritic Cells Are More Effective Than TCR Id Protein Vaccines for Active Immunotherapy of T Cell Lymphoma J. Immunol., November 1, 2002; 169(9): 5227 - 5235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Dhodapkar, J. Krasovsky, and K. Olson T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells PNAS, October 1, 2002; 99(20): 13009 - 13013. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
), tumor lysate
(
), or autologous primary myeloma cells (
). Controls included DCs
alone (
) and DCs pulsed an allogeneic tumor lysate from another
patient (
). In this study, patients 1 and 2 served as controls for
each other, as did patients 3 and 4. Results are representative of 3 independent experiments.
).
) against DCs pulsed with autologous tumor lysate at
different E:T ratios. (B) Comparison of the cytotoxicity of CTLs from
patients 1 (
) against DCs pulsed with
autologous tumor lysate (Auto-Lysate-DCs), allogeneic tumor lysate
from another patient (Allo-Lysate-DCs), autologous Id protein
(Id-DCs), unpulsed DCs (DCs) and autologous (Auto-PCs), or allogeneic
primary myeloma cells (Allo-PCs). The E:T ratio was 20:1. (C)
Inhibition by antibodies against MHC class I and class II or an
isotypic control IgG on the cytotoxicity of CTLs from patients 1 (
